FDA approves topical treatment for junctional, dystrophic EB

This is the first approved treatment for wounds associated with JEB and the second for patients with DEB, following the approval of a topical gene therapy in May 2023.
MDedge News

source https://www.medscape.com/s/viewarticle/fda-approves-topical-treatment-junctional-dystrophic-2023a1000wlt?src=rss